Organization Profile

Related Organization(s)

You just read:

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors

News provided by

Eli Lilly and Company

Jun 15, 2017, 10:35 ET